Clinical trials: Schizophrenia Disorders, open to volunteers
Schizophrenia, Bipolar I Disorder
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
- Trial name
- NCT05648591
- Testing
- Iloperidone
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vanda Pharmaceuticals
Schizo-affective Disorder, Non Organic Psychosis
Motivational Intervention for Patients With Schizophrenia
The goal of this clinical trial is to learn if a group therapy called the Positive Emotions Program for Schizophrenia (PEPS) can reduce apathy in adults aged 18 to 60 who have schizophrenia or a related psychotic disorder.
- Conditions
- Schizo-affective Disorder, Non Organic Psychosis, Schizophenia Disorder
- Trial name
- NCT07853079
- Testing
- Positive Emotion Program for Schizophrenia (PEPS), a psychotherapeutic intervention,
- Volunteers
- 88 people
- Sponsor
- University of Geneva, Switzerland
Schizophrenia Disorders
Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy
The goal of this clinical trial is to learn whether learning and belief updating change in response to the treatment of persecutory delusions, in individuals with schizophrenia-spectrum disorders. The main questions are: 1.
- Trial name
- VIP (NCT06835556)
- Testing
- Cognitive Behavioral Therapy, TAU
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Vanderbilt University Medical Center
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
SCHIZOPHRENIA 1 (Disorder)
Brain Imaging of DSP-2342
The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.
- Trial name
- NCT07850102
- Testing
- DSP-2342
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Bipolar Disorder, Major Depression
Effectiveness of mHealth Post-discharge Intervention for Patients With Severe Mental Illness
The overall aim of this program of research is to improve the continuity of care for patients with serious mental illness (SMI) by supporting a safer and more efficient bridge from hospital to outpatient care using a mobile…
- Conditions
- Bipolar Disorder, Major Depression, Schizophrenia
- Trial name
- tFOCUS (NCT05703412)
- Testing
- Transition-FOCUS mHealth Intervention, Check-In
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Butler Hospital
Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
In following guidelines for studying negative symptoms in schizophrenia, 60 patients aged 18-40, diagnosed with schizophrenia or schizoaffective disorder during the last ten years, will receive a combination of the iron chelator…
- Conditions
- Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder, Schizophrenia and Predominant Negative Symptoms
- Trial name
- IronMan (NCT07759895)
- Testing
- Deferiprone (DFP), N-Acetyl Cysteine (NAC)
- Where
- 2 sites in Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Amit Lotan
Schizophrenia, Bipolar Disorder
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
- Conditions
- Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
- Trial name
- NCT06229210
- Testing
- Lumateperone
- Where
- 65 sites in United States, Colombia and 1 more
- Volunteers
- 300 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia Spectrum Disorders (SSD)
Psychotherapy for Self-Disorders in Schizophrenia Spectrum Disorder
The primary goal of the VITALIZE study is to evaluate the feasibility of SELF-7, a novel phenomenologically informed psychotherapy for self-disorders, as an add-on to standard psychiatric outpatient treatment - Flexible Assertive…
- Trial name
- VITALIZE (NCT07841418)
- Testing
- SELF-7, F-ACT
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Psychiatric Research Unit, Region Zealand, Denmark
Schizophrenia Spectrum Disorders (SSD)
Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults…
- Trial name
- NCT07743645
- Testing
- Psychosocial intervention group
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia, Caregiver Burden
Psychological Resilience and Quality of Life Among Caregivers of Patients With Schizophrenia
Schizophrenia is a severe and chronic psychiatric disorder that requires long-term care management, placing family members who serve as informal caregivers under substantial psychological, physical, and financial strain.
- Conditions
- Schizophrenia, Caregiver Burden, Quality of Life
- Trial name
- NCT07837479
- Volunteers
- 130 people
- Sponsor
- Assiut University
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Early Psychosis, Psychosis
State Representation in Early Psychosis 2
This observational study will examine behavioral and electroencephalography measures related to state representation in individuals with early psychosis and healthy control participants.
- Conditions
- Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis
- Trial name
- STEP2 (NCT07834203)
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia, Treatment Resistant Depression (TRD)
Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment
The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments.
- Conditions
- Schizophrenia, Treatment Resistant Depression (TRD), Bipolar Disorder (BD), Catatonia
- Trial name
- BIO-INM (NCT07741981)
- Testing
- Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
Prucalopride for Cognitive Functioning in Schizophrenia
A core component of schizophrenia is neurocognitive impairment. The cognitive deficits are prominently seen in memory, attention, working memory, problem solving, processing speed and social cognition.
- Trial name
- NCT06474286
- Testing
- Prucalopride 1 MG
- Where
- India
- Volunteers
- 34 people
- Sponsor
- University of Pittsburgh
Schizophrenia / Schizoaffective Disorder
tACS for Self-Other Boundary in Schizophrenia
This clinical trial investigates whether a non-invasive brain stimulation technique called transcranial alternating current stimulation (tACS) can improve the ability to distinguish between "self" and "others" in patients with…
- Trial name
- NCT07818668
- Testing
- Transcranial Alternating Current Stimulation (tACS)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chunyan Zhu
Smoking Cessation, Nicotine Addiction
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation.
- Conditions
- Smoking Cessation, Nicotine Addiction, Schizophrenia
- Trial name
- NCT05276050
- Testing
- active F8-coil delivered rTMS, active H-coil delivered rTMS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia, Schizo Affective Disorder
Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA
A new mental health application will be developed for persons with schizophrenia and schizoaffective disorder. The aim is to look at whether it is feasible to use a mobile health application for improving medication adherence in…
- Trial name
- NCT06474325
- Testing
- Intervention via mobile application
- Where
- India
- Volunteers
- 44 people
- Sponsor
- University of Pittsburgh
Psychotic Disorders, Cannabis Use Disorder
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis…
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Cannabis Dependence, Cannabis Use
- Trial name
- NCT05445180
- Testing
- Contingency management
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute